Literature DB >> 27683949

Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand.

Wisit Prasithsirikul1, Sukanya Chongthawonsatid2, Pirapon June Ohata3, Siriwan Keadpudsa3, Virat Klinbuayaem4, Patsamon Rerksirikul3, Stephen J Kerr3, Kiat Ruxrungtham3,5, Jintanat Ananworanich3,6, Anchalee Avihingsanon3,5.   

Abstract

HIV/AIDS and anxiety/depression are interlinked. HIV-infected patients suffering from depression may be at risk for poor adherence which may contribute to HIV disease progression. Additionally, an HIV diagnosis and/or using certain antiretroviral agents may trigger symptoms of anxiety/depression. The objective of the study was to assess the prevalence and factors associated with anxiety and depression in HIV-infected patients from the Thai National HIV Treatment Program. This cross-sectional study was performed from January 2012 to December 2012 in HIV-infected out-patients, aged ≥18 years, from three HIV referral centers. Symptoms of anxiety and depression were measured using the Thai-validated Hospital Anxiety and Depression Scale (HADS). A score of ≥11 was defined as having anxiety and depression. Associated factors were assessed by multivariate logistic regression. Totally 2023 (56% males) patients were enrolled. All patients received antiretroviral therapy (ART) for a mean duration of 7.7 years. Median CD4 was 495 cells/mm3. Ninety-five percent had HIV-RNA < 50 copies/ml. Thirty-three percent were currently on efavirenz (EFV)-based ART. The prevalence of anxiety and depression were 4.8% and 3.1%, respectively. About 1.3% had both anxiety and depression. In multivariate logistic models, the female sex [OR = 1.6(95%CI 1.1-2.3), p = .01], having adherence <90% [OR = 2.2(95%CI 1.5-3.4), p < .001], fair/poor quality of life (QOL) [OR = 7.2 (95%CI 3.6-14.2), p < .001] and EFV exposure [OR = 1.6(95%CI 1.1-2.3), p = .01], were independently associated with having anxiety or depression. Our findings demonstrated that prevalence of depression and anxiety was low amongst virally suppressed, long-term antiretroviral-treated HIV-infected individuals. Some key characteristics such as the female sex, poor adherence, poor/fair QOL and EFV exposure are associated with anxiety and depression. These factors can be used to distinguish who would need a more in-depth evaluation for these psychiatric disorders.

Entities:  

Keywords:  Depression; HIV-1 infected patients; Thailand; anxiety; efavarenz; female

Mesh:

Year:  2016        PMID: 27683949     DOI: 10.1080/09540121.2016.1201194

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  12 in total

1.  In Utero Efavirenz Exposure and Neurodevelopmental Outcomes in HIV-exposed Uninfected Children in Botswana.

Authors:  Adam R Cassidy; Paige L Williams; Jean Leidner; Gloria Mayondi; Gbolahan Ajibola; Joseph Makhema; Penny A Holding; Kathleen M Powis; Oganne Batlang; Chipo Petlo; Roger Shapiro; Betsy Kammerer; Shahin Lockman
Journal:  Pediatr Infect Dis J       Date:  2019-08       Impact factor: 2.129

2.  Longitudinal trajectory of the association between quality of life and depression among people living with HIV in China: a mixed effects model.

Authors:  Wenxiu Sun; Hongzhou Lu; Feifei Huang; Cheng-Shi Shiu; Lin Zhang; Wei-Ti Chen
Journal:  AIDS Care       Date:  2021-10-20

3.  Anxiety and Depression Among Women Living with HIV: Prevalence and Correlations.

Authors:  Abdilahi Yousuf; Ramli Musa; Muhammad Lokman Md Isa; Siti Roshaidai Mohd Arifin
Journal:  Clin Pract Epidemiol Ment Health       Date:  2020-07-21

4.  Prevalence and Risks of Depression and Substance Use Among Adults Living with HIV in the Asia-Pacific Region.

Authors:  Jeremy L Ross; Awachana Jiamsakul; Anchalee Avihingsanon; Man Po Lee; Rossana Ditangco; Jun Yong Choi; Reena Rajasuriar; Sivaporn Gatechompol; Iris Chan; Maria Isabel Echanis Melgar; Jung Ho Kim; Meng Li Chong; Annette H Sohn; Matthew Law
Journal:  AIDS Behav       Date:  2022-06-06

5.  Antiretroviral therapy adherence based on information, motivation, and behavioral skills model and its association with depression among HIV-positive patients: Health promotion strategy towards the 909090 target.

Authors:  Mohammad Ali Morowatisharifabad; Ehsan Movahed; Jamileh Farokhzadian; Rohollah Nikooie; Mohsen Askarishahi; Reza Bidaki; Mahdieh Hosseinzadeh
Journal:  J Educ Health Promot       Date:  2019-10-24

6.  Depression and associated factors among HIV-positive youths attending antiretroviral therapy clinics in Jimma town, southwest Ethiopia.

Authors:  Derara Girma; Sahilu Assegid; Yenealem Gezahegn
Journal:  PLoS One       Date:  2021-01-06       Impact factor: 3.240

7.  Assessing the measurement invariance of the 10-item Centre for Epidemiological Studies Depression Scale and Beck Anxiety Inventory questionnaires across people living with HIV/AIDS and healthy people.

Authors:  Zahra Bagheri; Pegah Noorshargh; Zahra Shahsavar; Peyman Jafari
Journal:  BMC Psychol       Date:  2021-03-09

Review 8.  Depression and HIV Disease Progression: A Mini-Review.

Authors:  Abdilahi Yousuf; Siti Roshaidai Mohd Arifin; Ramli Musa; Muhammad Lokman Md Isa
Journal:  Clin Pract Epidemiol Ment Health       Date:  2019-12-31

Review 9.  The worldwide prevalence of anxiety in acquired immune deficiency syndrome patients: A systematic review and meta-analysis.

Authors:  Jeiran Rahmati; Saba Ahmadi; Sepideh Rezaei; Hossein Hosseinifard; Afsaneh Dehnad; Hosein Shabaninejad; Aidin Aryankhesal; Shabnam Ghasemyani; Samira Alihosseini; Zahra Mansour Kiaee; Zahra Noorani Mejareh; Sepideh Aghalou; Ahmad Ghashghaee; Mahnaz Shoghi; Mohammad Ahmadi Nasab; Anahita Khajehvand
Journal:  Med J Islam Repub Iran       Date:  2021-08-09

10.  Quality of life, anxiety and depression in patients with HIV/AIDS who present poor adherence to antiretroviral therapy: a cross-sectional study in Salvador, Brazil.

Authors:  Mónica Narváez Betancur; Liliane Lins; Irismar Reis de Oliveira; Carlos Brites
Journal:  Braz J Infect Dis       Date:  2017-05-21       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.